News Theranexus

Equities

ALTHX

FR0013286259

Real-time Euronext Paris Other stock markets 15:35:35 29/04/2024 BST			5-day change	1st Jan Change
1.155 ^EUR	+1.76%		+10.53%	+3.12%

04-19	Theranexus: share price rises following promising trial results	CF
03-11	Theranexus: CEO takes over as Chairman of the Board	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Theranexus : Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide	04-23	AT
Theranexus: share price rises following promising trial results	04-19	CF
Theranexus : Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1	04-18	AT
Theranexus: CEO takes over as Chairman of the Board	03-11	CF
Theranexus : THERANEXUS ANNOUNCES APPOINTMENT OF MATHIEU CHARVÉRIAT AS BOARD OF DIRECTORS CHAIRMAN	03-11	AT
Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS	02-14	AT
Certain Ordinary Shares of Theranexus Société Anonyme are subject to a Lock-Up Agreement Ending on 11-JAN-2024.	01-10	CI
Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2023	17/10/23	AT
Theranexus: promising results in Batten disease	29/09/23	CF
Theranexus : Theranexus : Highly Promising 12-month results in the Phase I/II trial of Batten-1	29/09/23	AT
Theranexus : THERANEXUS ANNOUNCES FIRST HALF 2023 FINANCIAL RESULTS	28/09/23	AT
Theranexus Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	28/09/23	CI
Theranexus : Theranexus raises around 3.1 million euros in fundraising	12/07/23	AT
Theranexus SociÃ©tÃ© Anonyme announced that it has received â‚¬2.470412 million in funding	11/07/23	CI
Theranexus: share price rises on promising trials	14/06/23	CF
Theranexus : Encouraging preliminary 6-month results in the Phase I/II trial of Batten-1 in Batten disease (CLN3)	14/06/23	AT
Theranexus: EMA positive on Phase 3 design	07/06/23	CF
Global markets live: Lucid, Under Armour, Coty, PayPal, Western Digital...	09/05/23
Erytech: renewed confidence in merger project	09/05/23	CF
Theranexus: FDA approval for Batten disease	09/05/23	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Theranexus

Equities

ALTHX

FR0013286259

Summary

Filters